Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-05-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
自愿披露关于氘恩扎鲁胺软胶囊新药上市申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by the company Hai Chuang Pharmaceutical Co., Ltd. regarding the approval of a new drug (氘恩扎鲁胺软胶囊) by the National Medical Products Administration (NMPA). It details the drug's basic information, clinical trial results, and potential impact on the company. The document is an official announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is a regulatory announcement about a significant company event related to product approval. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-05-29 Chinese
关于召开2025年第一季度业绩说明会的公告
Call Transcript Classification · 95% confidence The document is an announcement about the scheduling of a quarterly earnings explanation meeting (业绩说明会) for the first quarter of 2025. It provides details about the meeting time, location, format (online text interaction), participants, and how investors can submit questions. It references the prior release of the 2025 Q1 report but does not contain any financial data or analysis itself. The document is short (1447 characters) and serves to inform investors about the upcoming earnings call rather than presenting the earnings results or detailed financial statements. Therefore, it is best classified as a Call Transcript (CT) type document, specifically an announcement of an earnings call meeting, which fits the Call Transcript category as it relates to company conference calls and investor Q&A sessions.
2025-05-26 Chinese
中信证券股份有限公司关于海创药业股份有限公司2024年度持续督导跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2024年度持续督导跟踪报告" (2024 Annual Continuous Supervision Follow-up Report) issued by the sponsor (中信证券股份有限公司) for 海创药业股份有限公司, a listed company. It references regulatory frameworks related to securities issuance and listing, continuous supervision duties, and includes detailed discussion of company risks, financial data, R&D progress, and governance. The document contains substantive financial data for the 2024 fiscal year, including income, net profit, R&D expenses, and detailed risk disclosures. It is not a brief announcement or a certification letter but a comprehensive report on the company's ongoing supervision and performance for the year. This type of document aligns with an Audit Report / Information (AR) category, as it includes audit-related findings, internal control evaluations, and risk assessments, but is not a full Annual Report (10-K) or Interim Report (IR). It is also not a simple announcement or presentation. Therefore, the best fit is AR (Audit Report / Information). FY 2024
2025-05-14 Chinese
股东减持股份计划公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from a company regarding a shareholder's plan to reduce their shareholding. It details the shareholder's current holdings, the planned reduction amount, methods of reduction, timing, and compliance with relevant securities regulations. There is no financial data, earnings information, or management discussion. The document is a formal disclosure about a shareholder's intention to sell shares, which fits the category of Major Shareholding Notification (MRQ). The document length is 2532 characters, which is typical for such announcements and not a full report or earnings release.
2025-05-13 Chinese
2024年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2024年年度股东大会决议公告" which translates to "2024 Annual General Meeting Resolution Announcement." It details the date and location of the AGM, attendance, voting results on various proposals including the annual report, financial budget, profit distribution plan, and director remuneration. It also includes legal witness statements confirming the validity of the meeting and voting procedures. The document is a formal announcement of the voting results and resolutions passed at the AGM, not the full AGM materials or the annual report itself. The length is about 4,233 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-09 Chinese
北京通商（成都）律师事务所关于海创药业股份有限公司2024年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2024 Annual General Meeting (AGM) of the company. It details the procedures for convening the meeting, the qualifications of attendees, the voting procedures, and the results of the shareholder votes on various proposals. The document does not contain financial statements or detailed financial performance data but focuses on the legality and validity of the AGM process and voting outcomes. This matches the description of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. The document length is under 5,000 characters, but it contains detailed voting results, not just an announcement of a report publication. Therefore, the correct classification is DVA with high confidence.
2025-05-09 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.